EU panel supports approval of Novartis' COPD drug

07/29/2013 | Reuters

The European Medicines Agency's Committee for Medicinal Products for Human Use recommended the approval of Novartis' Ultibro Breezhaler, or QVA149, as a treatment for chronic obstructive pulmonary disease. The once-daily drug is a combination of long-acting beta2-adrenergic agonist indacaterol and long-acting muscarinic antagonist glycopyrronium.

View Full Article in:


Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Marlborough, MA
Test Technician
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT